664 related articles for article (PubMed ID: 11556834)
21. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
[TBL] [Abstract][Full Text] [Related]
22. Mutation screening of the CDKN2A promoter in melanoma families.
Harland M; Holland EA; Ghiorzo P; Mantelli M; Bianchi-Scarrà G; Goldstein AM; Tucker MA; Ponder BA; Mann GJ; Bishop DT; Newton Bishop J
Genes Chromosomes Cancer; 2000 May; 28(1):45-57. PubMed ID: 10738302
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
[TBL] [Abstract][Full Text] [Related]
24. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
25. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
[TBL] [Abstract][Full Text] [Related]
26. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
27. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
28. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
29. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
[TBL] [Abstract][Full Text] [Related]
30. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
[TBL] [Abstract][Full Text] [Related]
32. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
Jones R; Ruas M; Gregory F; Moulin S; Delia D; Manoukian S; Rowe J; Brookes S; Peters G
Cancer Res; 2007 Oct; 67(19):9134-41. PubMed ID: 17909018
[TBL] [Abstract][Full Text] [Related]
33. Germline splicing mutations of CDKN2A predispose to melanoma.
Loo JC; Liu L; Hao A; Gao L; Agatep R; Shennan M; Summers A; Goldstein AM; Tucker MA; Deters C; Fusaro R; Blazer K; Weitzel J; Lassam N; Lynch H; Hogg D
Oncogene; 2003 Sep; 22(41):6387-94. PubMed ID: 14508519
[TBL] [Abstract][Full Text] [Related]
34. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.
Lang J; Boxer M; MacKie RM
Br J Dermatol; 2005 Dec; 153(6):1121-5. PubMed ID: 16307646
[TBL] [Abstract][Full Text] [Related]
35. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
[TBL] [Abstract][Full Text] [Related]
37. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
Liu L; Lassam NJ; Slingerland JM; Bailey D; Cole D; Jenkins R; Hogg D
Oncogene; 1995 Jul; 11(2):405-12. PubMed ID: 7624155
[TBL] [Abstract][Full Text] [Related]
38. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
[TBL] [Abstract][Full Text] [Related]
39. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
40. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
